Christian Opherk1, Mariya Gonik, Marco Duering, Rainer Malik, Eric Jouvent, Dominique Hervé, Poneh Adib-Samii, Steve Bevan, Luigi Pianese, Serena Silvestri, Maria Teresa Dotti, Nicola De Stefano, Michael Liem, Elles M J Boon, Francesca Pescini, Chahin Pachai, Luc Bracoud, Bertram Müller-Myhsok, Thomas Meitinger, Natalia Rost, Leonardo Pantoni, Saskia Lesnik Oberstein, Antonio Federico, Michele Ragno, Hugh S Markus, Elisabeth Tournier-Lasserve, Jonathan Rosand, Hugues Chabriat, Martin Dichgans. 1. From Institute for Stroke and Dementia Research (C.O., M.G., M. Duering, R.M., M. Dichgans), and Department of Neurology (C.O.), Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany; Department of Neurology, DHU NeuroVasc, Hopital Lariboisiere, APHP, Paris, France (E.J., H.C.); Université Paris Diderot, Sorbonne Paris Cité, Génétique des Maladies Vasculaires, INSERM UMR-S740, Paris, France (D.H., E.T.-L.); Stroke and Dementia Research Centre, St George's University of London, London, United Kingdom (P.A.-S., S.B.); Neurology Division and Molecular Medicine Section, Mazzoni Hospital, Ascoli Piceno, Italy (L.P., S.S., M.R.); Department of Medicine, Surgery and Neurosciences, University of Siena, Italy (M.T.D., N.D.S., A.F.); Departments of Radiology (M.L.) and Clinical Genetics (E.M.J.B., S.L.O.), Leiden University Medical Center, Leiden, the Netherlands; Stroke Unit and Neurology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy (F.P., L.P.); BioClinica Inc, Lyon, France (C.P., L.B.); Max-Planck Institute of Psychiatry, Munich, Germany (B.M.-M.); Institute of Human Genetics, Helmholtz Center, Munich, Germany (T.M.); Center for Human Genetic Research and Department of Neurology, Massachusetts General Hospital, Boston, MA (N.R., J.R.); Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom (H.S.M.); Program in Medical and Population Genetics, Broad Institute, Cambridge, MA (J.R.); and Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (M. Dichgans).
Abstract
BACKGROUND AND PURPOSE: White matter hyperintensities (WMH) on MRI are a quantitative marker for sporadic cerebral small vessel disease and are highly heritable. To date, large-scale genetic studies have identified only a single locus influencing WMH burden. This might in part relate to biological heterogeneity of sporadic WMH. The current study searched for genetic modifiers of WMH volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a monogenic small vessel disease. METHODS: We performed a genome-wide association study to identify quantitative trait loci for WMH volume by combining data from 517 CADASIL patients collected through 7 centers across Europe. WMH volumes were centrally analyzed and quantified on fluid attenuated inversion recovery images. Genotyping was performed using the Affymetrix 6.0 platform. Individuals were assigned to 2 distinct genetic clusters (cluster 1 and cluster 2) based on their genetic background. RESULTS: Four hundred sixty-six patients entered the final genome-wide association study analysis. The phenotypic variance of WMH burden in CADASIL explained by all single nucleotide polymorphisms in cluster 1 was 0.85 (SE=0.21), suggesting a substantial genetic contribution. Using cluster 1 as derivation and cluster 2 as a validation sample, a polygenic score was significantly associated with WMH burden (P=0.001) after correction for age, sex, and vascular risk factors. No single nucleotide polymorphism reached genome-wide significance. CONCLUSIONS: We found a polygenic score to be associated with WMH volume in CADASIL subjects. Our findings suggest that multiple variants with small effects influence WMH burden in CADASIL. The identification of these variants and the biological pathways involved will provide insights into the pathophysiology of white matter disease in CADASIL and possibly small vessel disease in general.
BACKGROUND AND PURPOSE: White matter hyperintensities (WMH) on MRI are a quantitative marker for sporadic cerebral small vessel disease and are highly heritable. To date, large-scale genetic studies have identified only a single locus influencing WMH burden. This might in part relate to biological heterogeneity of sporadic WMH. The current study searched for genetic modifiers of WMH volume in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a monogenic small vessel disease. METHODS: We performed a genome-wide association study to identify quantitative trait loci for WMH volume by combining data from 517 CADASIL patients collected through 7 centers across Europe. WMH volumes were centrally analyzed and quantified on fluid attenuated inversion recovery images. Genotyping was performed using the Affymetrix 6.0 platform. Individuals were assigned to 2 distinct genetic clusters (cluster 1 and cluster 2) based on their genetic background. RESULTS: Four hundred sixty-six patients entered the final genome-wide association study analysis. The phenotypic variance of WMH burden in CADASIL explained by all single nucleotide polymorphisms in cluster 1 was 0.85 (SE=0.21), suggesting a substantial genetic contribution. Using cluster 1 as derivation and cluster 2 as a validation sample, a polygenic score was significantly associated with WMH burden (P=0.001) after correction for age, sex, and vascular risk factors. No single nucleotide polymorphism reached genome-wide significance. CONCLUSIONS: We found a polygenic score to be associated with WMH volume in CADASIL subjects. Our findings suggest that multiple variants with small effects influence WMH burden in CADASIL. The identification of these variants and the biological pathways involved will provide insights into the pathophysiology of white matter disease in CADASIL and possibly small vessel disease in general.
Entities:
Keywords:
CADASIL; cerebral small vessel diseases; genetics; genome-wide association study; leukoaraiosis
Authors: Lauren E Salminen; Peter R Schofield; Kerrie D Pierce; Thomas E Conturo; David F Tate; Elizabeth M Lane; Jodi M Heaps; Jacob D Bolzenius; Laurie M Baker; Erbil Akbudak; Robert H Paul Journal: Age (Dordr) Date: 2014-07-01
Authors: Sandro Marini; William J Devan; Farid Radmanesh; Laura Miyares; Timothy Poterba; Björn M Hansen; Bo Norrving; Jordi Jimenez-Conde; Eva Giralt-Steinhauer; Roberto Elosua; Elisa Cuadrado-Godia; Carolina Soriano; Jaume Roquer; Christina E Kourkoulis; Alison M Ayres; Kristin Schwab; David L Tirschwell; Magdy Selim; Devin L Brown; Scott L Silliman; Bradford B Worrall; James F Meschia; Chelsea S Kidwell; Joan Montaner; Israel Fernandez-Cadenas; Pilar Delgado; Steven M Greenberg; Arne Lindgren; Charles Matouk; Kevin N Sheth; Daniel Woo; Christopher D Anderson; Jonathan Rosand; Guido J Falcone Journal: Stroke Date: 2018-06-18 Impact factor: 7.914
Authors: Benno Gesierich; Christian Opherk; Jonathan Rosand; Mariya Gonik; Rainer Malik; Eric Jouvent; Dominique Hervé; Poneh Adib-Samii; Steve Bevan; Luigi Pianese; Serena Silvestri; Maria T Dotti; Nicola De Stefano; Jeroen van der Grond; Elles M J Boon; Francesca Pescini; Natalia Rost; Leonardo Pantoni; Saskia A Lesnik Oberstein; Antonio Federico; Michele Ragno; Hugh S Markus; Elisabeth Tournier-Lasserve; Hugues Chabriat; Martin Dichgans; Marco Duering; Michael Ewers Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Poneh Adib-Samii; William Devan; Matthew Traylor; Silvia Lanfranconi; Cathy R Zhang; Lisa Cloonan; Guido J Falcone; Farid Radmanesh; Kaitlin Fitzpatrick; Allison Kanakis; Peter M Rothwell; Cathie Sudlow; Giorgio B Boncoraglio; James F Meschia; Chris Levi; Martin Dichgans; Steve Bevan; Jonathan Rosand; Natalia S Rost; Hugh S Markus Journal: Stroke Date: 2014-12-30 Impact factor: 7.914
Authors: Ilaria Di Donato; Silvia Bianchi; Nicola De Stefano; Martin Dichgans; Maria Teresa Dotti; Marco Duering; Eric Jouvent; Amos D Korczyn; Saskia A J Lesnik-Oberstein; Alessandro Malandrini; Hugh S Markus; Leonardo Pantoni; Silvana Penco; Alessandra Rufa; Osman Sinanović; Dragan Stojanov; Antonio Federico Journal: BMC Med Date: 2017-02-24 Impact factor: 8.775